Shi-zhe Zhang
Zhongshan, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Irbesartan inhibits metastasis by interrupting the adherence of tumor cell to endothelial cell induced by angiotensin II in hepatocellular carcinoma.
Journal: Annals of translational medicine
Published: March 12, 2021
PCSK9 promotes tumor growth by inhibiting tumor cell apoptosis in hepatocellular carcinoma.
Journal: Experimental hematology & oncology
Published: January 12, 2021
Renin-angiotensin inhibitors were associated with improving outcomes of hepatocellular carcinoma with primary hypertension after hepatectomy.
Journal: Annals of translational medicine
Published: February 12, 2020
NT5DC2 promotes tumor cell proliferation by stabilizing EGFR in hepatocellular carcinoma.
Journal: Cell death & disease
Published: December 01, 2019
Correction to: miR-182-5p promotes hepatocellular carcinoma progression by repressing FOXO3a.
Journal: Journal of hematology & oncology
Published: April 04, 2018
CD31 regulates metastasis by inducing epithelial-mesenchymal transition in hepatocellular carcinoma via the ITGB1-FAK-Akt signaling pathway.
Journal: Cancer letters
Published: February 19, 2018
miR-182-5p promotes hepatocellular carcinoma progression by repressing FOXO3a.
Journal: Journal of hematology & oncology
Published: December 15, 2017
PFKFB3 blockade inhibits hepatocellular carcinoma growth by impairing DNA repair through AKT.
Journal: Cell death & disease
Published: November 22, 2017
The Rho GTPase Rnd1 inhibits epithelial-mesenchymal transition in hepatocellular carcinoma and is a favorable anti-metastasis target.
Journal: Cell death & disease
Published: September 30, 2017
Showing 1-9 of 9
Last Updated: 09/26/2026